Turn on, Tune in, Cash Out … The US Right Used to Fear Psychedelics. Now It Wants to Sell Them | Kojo Koram

Why It Matters

The policy shift unlocks a multibillion‑dollar market and could reshape mental‑health treatment in the United States, while aligning powerful political and tech capital with drug‑reform initiatives.

Key Takeaways

• Trump signed executive order fast‑tracking ibogaine medical approvals
• RFK Jr and Joe Rogan publicly back psychedelic policy shift
• Forbes forecasts psychedelic mushroom market > $3.3 bn by 2031
• Peter Thiel and Sergey Brin invested $140 m in psychedelic biotech
• Veterans and police groups lobby for psychedelic PTSD therapies

Pulse Analysis

The recent executive order represents a watershed moment for U.S. drug policy, flipping the script on a legacy of anti‑psychedelic sentiment that once defined the Republican platform. By aligning with high‑profile advocates like RFK Jr and Joe Rogan, the Trump administration signals that psychedelic therapies are no longer a fringe curiosity but a legitimate component of the national health strategy. This political endorsement dovetails with a broader cultural reappraisal, as clinical trials increasingly demonstrate efficacy for depression, PTSD, and suicidal ideation, prompting legislators on both sides of the aisle to reconsider longstanding prohibitions.

Financial markets have responded with enthusiasm. Forbes projects the global psychedelic mushroom sector to surpass $3.3 bn by 2031, a trajectory fueled by venture capital inflows from Silicon Valley stalwarts. Peter Thiel’s $125 m 2020 round and Sergey Brin’s $15 m 2024 investment illustrate a growing conviction that psychedelic biotech can deliver returns comparable to blockbuster drugs like Ozempic. The convergence of biotech innovation, celebrity endorsement, and political will creates a fertile environment for rapid commercialization, positioning the United States as a potential hub for next‑generation mental‑health solutions.

Yet the rapid ascent raises critical questions about access, regulation, and equity. While veterans and police officers are championing psychedelic treatments for PTSD, the concentration of funding among a handful of tech magnates could concentrate market power and influence policy outcomes. Policymakers must balance accelerated approval pathways with rigorous safety standards to avoid repeating past missteps. If managed responsibly, the psychedelic renaissance could democratize effective therapies for a billion people grappling with mental‑health disorders; if not, it risks becoming another lucrative niche controlled by a privileged few.